Medarex and Boehringer Ingelheim announce antibody development agreement

16-Jun-2005

Medarex, Inc. and Boehringer Ingelheim announced an agreement for the development of fully human therapeutic antibodies. Boehringer Ingelheim intends to use Medarex's UltiMAb Human Antibody Development System® to generate antibodies to disease targets. Financial terms were not disclosed.

Pursuant to the agreement, Boehringer Ingelheim plans to develop and commercialize fully human antibody therapeutics for a variety of diseases, including cancer. Medarex will receive technology access fees and could receive additional license fees and milestone payments as well as royalties on commercial sales of any products that may result from this agreement.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous